angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8).
We comply with the HONcode standard for trustworthy health information - Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4). It is felt the benefit of treatment of MDR-TB outweighs the small potential risk of adverse reactions. Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t½: 6 - 8 hours). COVID-19 is an emerging, rapidly evolving situation. Some undesirable effects (e.g. Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. • in patients with history of tendon disorders related to fluoroquinolone administration. Other resistance mechanisms such as permeation barriers (common in Cross-resistance between levofloxacin and other fluoroquinolones is observed.Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/l).1. Therefore, concomitant use of corticosteroids should be avoided.At the first sign of tendinitis (e.g. When used by inhalation in adults.

Anti-TB drug sheets and patient instructions; Group 3 ; Levofloxacin (Lfx) Therapeutic action – Antibacterial (fluoroquinolone) with bactericidal activity. • Acute exacerbation of chronic obstructive pulmonary disease including bronchitis hypokalaemia, hypomagnesaemia)- cardiac disease (e.g. Levofloxacin 500mg Film-coated Tablets may therefore be administered regardless of food intake. Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.Approximately 30-40% of levofloxacin is bound to serum protein.

% RIF 600 mg / 48 kg RIF 600 mg / 80 kg ... • Ethambutol, levofloxacin, cycloserine vary with renal function

The Cmax/MIC and AUC0-24h/MIC ratios are the best predictive parameters for efficacy of levofloxacin treatment and will be estimated.
Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations.Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones.

• Complicated skin and soft tissue infections/complicated skin and skin structure infectionsFor the above-mentioned infections Levofloxacin 500mg Film-coated Tablets should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. The usual dose of Levofloxacin Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours, as indicated by infection and described in Table 1. It allows continued monitoring of the benefit/risk balance of the medicinal product. Levofloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.In patients treated with levofloxacin, determination of opiates in urine may give false-positive results.

Richeldi L(1), Covi M, Ferrara G, Franco F, Vailati P, Meschiari E, Fabbri LM, Velluti G. Author information: (1)Clinica di Malattie dell'Apparato Respiratorio, Università degli Studi di Modena e Reggio Emilia, Italy. Since levofloxacin is excreted mainly by the kidneys, the dose of levofloxacin should be adjusted in patients with renal impairment (see section 4.2). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 “Tendinitis and tendon rupture” and “QT interval prolongation”).

antecedent adverse event to first-line TB drugs, whereas 18% received levofloxacin because of resistance) and concurrent use of first-line drugs (majority of patients in the levofloxacin arm were not receiving concurrent isoniazid or rifampin). DOSAGE Adults: 10–15 mg/kg once daily (usually 750mg to 1000mg once daily). QT interval prolongation)In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.There is no clinically relevant interaction with food.

due to interstitial nephritis)General disorders and administration site conditions*Pain (including pain in back, chest, and extremities)* Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).Other undesirable effects which have been associated with fluoroquinolone administration include:Reporting suspected adverse reactions after authorisation of the medicinal product is important. Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.